Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.
Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.
Parenteral nutrition for patients requiring caloric and amino acid intake when oral or enteral nutrition is not possible, insufficient, or contraindicated,Off-label: May be used in specific metabolic disorders requiring controlled amino acid and dextrose delivery
Parenteral nutrition for patients with inadequate oral or enteral intake,Prevention of nitrogen loss in catabolic states,Treatment of negative nitrogen balance
Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.
Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.
Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture.
Amino acids: 0.5-1 hour for free amino acids; terminal half-life of infused nitrogen is approximately 2-4 hours; clinical context: reflects rapid uptake and metabolism.
Dextrose undergoes glycolysis and oxidation via the citric acid cycle. Amino acids are deaminated and metabolized via ureagenesis and gluconeogenesis.
Amino acids are metabolized primarily in the liver via deamination, transamination, and other pathways. The carbon skeletons enter the citric acid cycle or gluconeogenesis, and nitrogen is converted to urea.
The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination.
Renal (primarily as amino acids and metabolites); ~90% of infused amino nitrogen is excreted renally within 24-48 hours; <5% biliary/fecal.
Amino acids: variable, generally low (0-30%) bound to albumin and other plasma proteins. Dextrose: negligible protein binding. Electrolytes: calcium is ~40-50% bound to albumin and other proteins; magnesium ~30%; phosphate ~10-20%; others minimal. Overall, component-specific.
Amino acids: negligible protein binding (<5%); albumin binds some tryptophan and branched-chain amino acids minimally.
Not applicable as a single entity. Amino acids distribute into total body water (~0.5-0.6 L/kg). Dextrose distributes into extracellular fluid (~0.2 L/kg) initially, then intracellularly. Electrolytes distribute according to their physiological compartments. No meaningful Vd for the mixture.
Amino acids: 0.3-0.5 L/kg (approximates extracellular fluid volume); clinical meaning: distributes primarily in ECF.
Intravenous: 100% bioavailability as it is administered directly into the bloodstream. Not applicable to oral or other routes.
Intravenous: 100% (only route of administration); not absorbed orally as parenteral formulation.
For GFR 30-59 m L/min: reduce volume by 25-50%; monitor electrolytes. For GFR 15-29 m L/min: reduce volume by 50-75%; avoid if severe renal impairment. For GFR <15 m L/min: contraindicated unless on renal replacement therapy; use with caution and adjust electrolytes.
GFR <50 m L/min: reduce dose to 0.5-0.8 g/kg/day. GFR <15 m L/min: avoid or use with extreme caution, monitor serum amino acids.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce amino acid dose by 50%; monitor ammonia. Child-Pugh Class C: avoid due to risk of hepatic encephalopathy; alternative nutrition may be needed.
Child-Pugh class B: reduce dose by 50%. Child-Pugh class C: contraindicated due to risk of hepatic encephalopathy.
Dose based on weight (kg) and caloric needs. Typical: 10-15 m L/kg/day initially, titrate to 20-30 m L/kg/day. Maximum dextrose infusion rate: 0.5 g/kg/hr for neonates, 1 g/kg/hr for older children. Use with caution in low birth weight infants.
Neonates: 2-3 g/kg/day IV. Infants/children: 1.5-2.5 g/kg/day IV. Adjust based on metabolic status and growth.
Elderly patients often require lower doses due to decreased renal function; start at lower infusion rates (e.g., 1-2 m L/kg/hr). Monitor fluid balance, electrolytes, and renal function closely. Dose adjustment based on GFR is recommended.
Initiate at low end of adult dose (1 g/kg/day IV), monitor renal function and adjust accordingly; consider reduced metabolic clearance.
Not for intravenous infusion unless admixed with appropriate electrolytes and vitamins. Do not administer simultaneously with blood through the same infusion site because of risk of pseudoagglutination. Use with caution in patients with severe hepatic or renal disease.
None
Monitor fluid balance, electrolyte concentrations, and acid-base status,Risk of hyperglycemia, hyperosmolarity, and metabolic acidosis,Hepatic and renal impairment require dose adjustment,Contains aluminum which may be toxic with prolonged use,Use with caution in patients with heart failure or pulmonary edema
Risk of hyperammonemia, especially in patients with hepatic impairment or inborn errors of urea cycle,Electrolyte imbalances may occur; monitor serum electrolytes frequently,Monitor for signs of infection at infusion site,Use caution in patients with renal impairment, as accumulation of amino acids may occur,May cause metabolic acidosis in certain patients
Hypersensitivity to any component,Severe hyperglycemia or diabetes mellitus with ketoacidosis,Severe hepatic or renal failure (unless adjusted),Intracranial or intraspinal hemorrhage,Anuria (for electrolyte-containing formulations)
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria),Severe hepatic failure with hyperammonemia,Severe renal failure without dialysis support,Patients with uncorrected electrolyte imbalances
Do not administer with any oral food or enteral nutrition unless specifically ordered; interactions depend on individual patient condition. Concomitant use of oral hypoglycemic agents may require dose adjustment due to dextrose content.
No direct food interactions, but ensure adequate non-protein calorie intake (carbohydrates, fats) to prevent amino acid utilization for energy. Avoid concurrent use with high-protein oral diets without medical supervision. For patients with phenylketonuria (PKU), verify product composition as some contain phenylalanine.
CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, but no evidence of malformations. Second and third trimesters: no known fetal risks. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose control is poor.
Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this formulation. In the first trimester, the risk of teratogenicity is theoretical; essential amino acids are necessary for fetal development, but excesses or imbalances may be harmful. During the second and third trimesters, supplementation may be beneficial for maternal and fetal nutrition, but potential risks include metabolic acidosis or electrolyte disturbances if not properly monitored.
Components are endogenous substances normally found in breast milk. Dextrose and amino acids are present in milk; no adverse effects expected. M/P ratio not established. Safe to use during breastfeeding when clinically indicated.
Aminosyn 10% is not excreted into breast milk in significant amounts; its components are endogenous substances. The M/P ratio is not applicable as it is not a drug with active transport. Maternal use during breastfeeding is considered safe if the infusion is necessary for maternal health. No adverse effects on the nursing infant are expected.
Pregnancy increases plasma volume and renal clearance, but dosing adjustments are not typically required. Monitor glucose and electrolyte levels to avoid hyperglycemia or electrolyte imbalances. Use standard parenteral nutrition guidelines with close monitoring.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering amino acid clearance. However, no specific dose adjustments are established for Aminosyn 10%. Dosage should be individualized based on nitrogen balance, weight gain, and metabolic parameters. Close monitoring of amino acid levels and metabolic status is recommended to avoid toxicities or deficiencies.
This formulation provides 4.25% amino acids and 25% dextrose with electrolytes and calcium for total parenteral nutrition. Contains sulfite-free preparation; confirm patient's sulfite allergy status. Monitor serum electrolytes, blood glucose, and liver function tests; adjust infusion rate to avoid refeeding syndrome in malnourished patients.
Use central line administration for concentrations >5% to reduce thrombophlebitis risk. Monitor serum electrolytes, BUN, glucose, and liver function tests frequently. Adjust infusion rate based on metabolic tolerance; start at 100 m L/hr and increase gradually. Contraindicated in severe hepatic disease, uremia, or maple syrup urine disease. Do not use as a sole source of nutrition; provide concurrent calories from carbohydrates and fats.
This medication is given intravenously to provide nutrition when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or fever.,You may need regular blood tests to monitor your blood sugar, electrolyte levels, and liver function.,Do not suddenly stop the infusion without consulting your healthcare provider.,Inform your healthcare provider if you have diabetes, as this solution contains dextrose (sugar).
This solution provides amino acids for protein building when you cannot eat normally.,Report signs of infection at catheter site: redness, swelling, pain, or drainage.,Common side effects include nausea, flushing, and warmth during infusion.,You will need regular blood tests to monitor kidney, liver, and metabolic function.,Inform your doctor if you have diabetes, kidney disease, or a history of gout.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10%, answered by our medical review team.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.. AMINOSYN 10% is a Parenteral Nutrition Solution that works by Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.. The standard adult dose of AMINOSYN 10% is: Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, b. AMINOSYN 10% is classified as Category C. Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.